A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Health care providers treating people with COPD also need to focus on the person's socioeconomic factors, along with ...

Winter is prime time for COPD. You can’t get rid of the disease, but treatment can improve quality of life.Key takeaways:COPD ...

An estimated 30 million Americans are affected by chronic obstructive pulmonary disease (COPD), but surprisingly, only 17 million have received a diagnosis. Texas alone accounts for 1.2 million of ...

Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.

University of California, San Francisco and the University of Alabama at Birmingham researchers have identified a link ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Socially isolated older adults with chronic obstructive pulmonary disease (COPD) had an increased risk of mortality ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the ...

This broad utilization across all patient types is consistent with market research and supports our belief that Ohtuvayre’s bronchodilator ... advancement for COPD patients and can re-define ...

Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti ...